preoperative docetaxel chemotherapy and radical prostatectomy for metastatic prostate cancer

Efficacy and safety of preoperative docetaxel chemotherapy and radical prostatectomy for untreated metastatic prostate cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1031180387

Enrollment

Registered

2019-03-20

Start date

2019-07-17

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostate Cancer Metastatic, untreated, high-risk

Interventions

Taxane chemotherapy,cytoreductive prostatectomy

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: metastatic prostate cancer

Exclusion criteria

Exclusion criteria: Castration-Resistant Prostate Cancer, treated prostate cancer

Design outcomes

Primary

Measure	Time frame
Progression-free survival	—

Secondary

Measure	Time frame
PSA-recurrence-free survival, perioperative complication rate, time to CRPC(castration-resistant prostate cancer)	—

Contacts

Public ContactMasayoshi Nagata

Juntendo University

m-nagata@juntendo.ac.jp+81-3-3813-3111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026